Access this new episode here:

Access on GOG GYN-LIVE Podcast

Access on YouTube

The post Accrual Culture: Top Points for Site Selection – Enrollement appeared first on GOG.

Welcome to the official podcast of The GOG Foundation, Inc.—a nonprofit organization dedicated to advancing excellence in clinical and scientific research for gynecologic cancers. From ovarian and uterine to cervical, vaginal, and vulvar malignancies, our investigators and institutions are at the forefront of innovation, shaping the future of cancer care.

 

Each episode features leading experts, groundbreaking trial insights, and real-world stories that illuminate the evolving landscape of gynecologic oncology. Whether you’re a clinician, researcher, patient advocate, or survivor, join us as we explore the science, the people, and the progress driving better outcomes and quality of life for patients everywhere.

 

Subscribe and List

 

Listen to GOG GYN-LIVE using one of many popular podcasting apps or directories.

 

Subsribe by RSS Feed

 

Click here to access the GOG GYN-LIVE Podcast website page.

The post GOG GYN-LIVE PODCAST appeared first on GOG.

PRESS RELEASE

For Immediate Release

Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Jan. 22, 2026– Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer, met its overall survival (OS) primary endpoint.

Click here to read full press release.

The post ROSELLA GOG-3073 | ENGOT-OV72<br>Press Release</br> appeared first on GOG.

Click here to download a PDF copy of the GOG Partners Connection Newsletter.

The post GOG Partners Connection Quarterly Newsletter – December 2025 appeared first on GOG.

PRESS RELEASE

For Immediate Release

Philadelphia, PA, USA, December 9, 2025, First Patient Enrolled in GOG-3133/ FRAmework-01 Phase 3 Study Evaluating Sofetabart Mipitecan (LY4170156), a Novel ADC Targeting Folate Receptor Alpha (FRα), in Recurrent Ovarian Cancer

The GOG Foundation, Inc. is proud to announce the enrollment of the first patient in GOG-3133, a pivotal Phase 3 clinical trial titled FRAmework-01: A Two-Part Phase 3 Study of LY4170156 versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and LY4170156 plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer. The study is sponsored by Eli Lilly and Company and conducted in collaboration with The GOG Foundation, Inc.

Click here to read full press release.

The post GOG-3133/ FRAmework-01/ ENGOT-ov97/ <br>GINECO-NOGGO Press Release</br> appeared first on GOG.

Click here to download a PDF copy of the GOG Partners Connection Newsletter.

The post GOG Partners Connection Quarterly Newsletter – September 2025 appeared first on GOG.

PUBLICATION

The post The GOG Foundation and EVA/LACOG Partnership: A Collaborative Strategic Alliance for Clinical Trial Execution Publication appeared first on GOG.

PUBLICATION

Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: The GOG Foundation, Inc’s Scholar Career Development Award and New Investigator Program

HIGHLIGHTS

Click here to read the full publication.

The post IJGC GOG Foundation Scholar Career Development Award and New Investigator Program Publication appeared first on GOG.